Drug Profile
SAR 389644
Alternative Names: SAR389644Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator sanofi-aventis
- Developer Sanofi
- Class Antiasthmatics
- Mechanism of Action Prostaglandin D2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Allergic rhinitis; Asthma
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Allergic-rhinitis in France
- 16 Jul 2016 No recent reports of development identified for phase-I development in Asthma in France
- 22 Apr 2008 Phase-I clinical trials in Allergic rhinitis in France (unspecified route)